Aehr Test Systems (AEHR) has had the highest return this year by a mid-cap US stock, returning 514.8%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Aehr Test Systems (AEHR) | 2026 | 514.8% |
Erasca (ERAS) | 2026 | 400.81% |
AXT (AXTI) | 2026 | 356.22% |
MaxLinear (MXL) | 2026 | 316.88% |
Twist Bioscience (TWST) | 2026 | 294.61% |
Immunitybio (IBRX) | 2026 | 283.17% |
Enliven Therapeutics (ELVN) | 2026 | 273.68% |
Ichor (ICHR) | 2026 | 260.55% |
Oruka Therapeutics (ORKA) | 2026 | 254.34% |
10X Genomics (TXG) | 2026 | 254.08% |
Ultra Clean (UCTT) | 2026 | 246.79% |
P3 Health Partners (PIII) | 2026 | 230.23% |
Veradermics (MANE) | 2026 | 220.74% |
Spyre Therapeutics (SYRE) | 2026 | 217.74% |
Definium Therapeutics (DFTX) | 2026 | 216.96% |
Pulse Biosciences (PLSE) | 2026 | 213.23% |
Maase (MAAS) | 2026 | 204.07% |
Abcellera Biologics (ABCL) | 2026 | 202.78% |
Hemab Therapeutics Holdings, Inc Common Stock (COAG) | 2026 | 197.11% |
Penguin Solutions (PENG) | 2026 | 195.42% |
Tango Therapeutics (TNGX) | 2026 | 189.04% |
Iridium Communications (IRDM) | 2026 | 186.02% |
Dianthus Therapeutics (DNTH) | 2026 | 173.44% |
Sellas Life Sciences (SLS) | 2026 | 164.49% |
Alumis (ALMS) | 2026 | 161.51% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.